Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

New developments in castrate-resistant prostate cancer.

Shore N, Mason M, de Reijke TM.

BJU Int. 2012 Jun;109 Suppl 6:22-32. doi: 10.1111/j.1464-410X.2012.11217.x. Review.

2.

[The treatment of castration-resistant prostate cancer].

Petrányi Á.

Magy Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3. Review. Hungarian.

3.

Emerging treatment options for patients with castration-resistant prostate cancer.

George D, Moul JW.

Prostate. 2012 Feb;72(3):338-49. doi: 10.1002/pros.21435. Epub 2011 Jul 11. Review.

PMID:
21748753
4.

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Abdulla A, Kapoor A.

Can Urol Assoc J. 2011 Apr;5(2):120-33. doi: 10.5489/cuaj.10160.

5.

New and emerging agents for the treatment of castration-resistant prostate cancer.

Higano CS, Crawford ED.

Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. doi: 10.1016/j.urolonc.2011.08.013. Review.

PMID:
22074657
6.

New agents for prostate cancer.

Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J.

Ann Oncol. 2014 Sep;25(9):1700-9. doi: 10.1093/annonc/mdu038. Epub 2014 Mar 20. Review.

7.

Current and emerging treatments in the management of castration-resistant prostate cancer.

Shapiro D, Tareen B.

Expert Rev Anticancer Ther. 2012 Jul;12(7):951-64. doi: 10.1586/era.12.59. Review.

PMID:
22845410
8.

Emerging targeted therapies for castration-resistant prostate cancer.

Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N.

Front Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073. eCollection 2012.

9.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

10.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
11.

Update on castrate-resistant prostate cancer: 2010.

Lassi K, Dawson NA.

Curr Opin Oncol. 2010 May;22(3):263-7. doi: 10.1097/CCO.0b013e3283380939.

PMID:
20177381
12.

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J.

BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.

13.

Novel strategies in the treatment of castration-resistant prostate cancer (Review).

Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.

Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9. Review.

PMID:
22322981
14.

Emerging novel therapies for advanced prostate cancer.

Osanto S, Van Poppel H.

Ther Adv Urol. 2012 Feb;4(1):3-12. doi: 10.1177/1756287211432777.

15.

New therapeutics to treat castrate-resistant prostate cancer.

Acar O, Esen T, Lack NA.

ScientificWorldJournal. 2013 May 27;2013:379641. doi: 10.1155/2013/379641. Print 2013. Review.

16.

Castration-resistant prostate cancer: current and emerging treatment strategies.

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN.

Drugs. 2010 May 28;70(8):983-1000. doi: 10.2165/10898600-000000000-00000. Review.

PMID:
20481655
17.

Recent advances in second-line treatment of castration-resistant prostate cancer.

Ong M, Winquist E.

Curr Opin Support Palliat Care. 2011 Sep;5(3):199-205. doi: 10.1097/SPC.0b013e32834903aa. Review.

PMID:
21734586
18.

Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.

BJU Int. 2012 Apr;109(7):968-85. doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28. Review.

19.

Novel options for the treatment of castration-resistant prostate cancer.

Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.

World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20. Review.

PMID:
22101903
20.

New perspectives in the therapy of castration resistant prostate cancer.

Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G.

Curr Drug Targets. 2012 Dec;13(13):1676-86. Review.

PMID:
23043326
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk